Early detection of tumour immune-rejection using magnetic resonance imaging

被引：12

作者：

Hu, DE

Beauregard, DA

Bearchell, MC

Thomsen, LL

Brindle, KM

机构：

[1] Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England

[2] GlaxoSmithKline, Immunomodulat Sect, Immunotherapeut Dept, Stevenage SG1 2NY, Herts, England

来源：

BRITISH JOURNAL OF CANCER | 2003年 / 88卷 / 07期

基金：

英国医学研究理事会;

关键词：

tumours; immunotherapy; magnetic resonance imaging;

D O I：

10.1038/sj.bjc.6600814

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Dynamic contrast agent-enhanced magnetic resonance imaging measurements of the perfusion of an immunogenic murine tumour showed that immune rejection was preceded by an increase in the apparent vascular volume of the tumour. This increase in vascularity, which has been observed previously in other tumours undergoing immune rejection, was confirmed by histological analysis of tumour sections obtained postmortem. Magnetic resonance imaging measurements similar to this could be used in the clinic to monitor the early responses of tumours to immunotherapy, before there is any change in tumour growth rate or volume.

引用

页码：1135 / 1142

页数：8

共 50 条

[1] Paramagnetic lanthanide(III) complexes as pH-sensitive chemical exchange saturation transfer (CEST) contrast agents for MRI applications
Aime, S
Barge, A
Delli Castelli, D
Fedeli, F
Mortillaro, A
Nielsen, FU
Terreno, E
[J]. MAGNETIC RESONANCE IN MEDICINE, 2002, 47 (04) : 639 - 648
[2] Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status
Beauregard, DA
Thelwall, PE
Chaplin, DJ
Hill, SA
Adams, GE
Brindle, KM
[J]. BRITISH JOURNAL OF CANCER, 1998, 77 (11) : 1761 - 1767
[3] Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS
Beauregard, DA
Pedley, RB
Hill, SA
Brindle, KM
[J]. NMR IN BIOMEDICINE, 2002, 15 (02) : 99 - 105
[4] Beauregard DA, 2001, CANCER RES, V61, P6811
[5] HISTOLOGICAL REGRESSION IN PRIMARY CUTANEOUS MELANOMA - RECOGNITION, PREVALENCE AND SIGNIFICANCE
BLESSING, K
MCLAREN, KM
[J]. HISTOPATHOLOGY, 1992, 20 (04) : 315 - 322
[6] BODURTHA AJ, 1976, CANCER-AM CANCER SOC, V37, P735, DOI 10.1002/1097-0142(197602)37:2<735::AID-CNCR2820370221>3.0.CO
[7] 2-Z
[8] BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[9] Brossart P, 1997, J IMMUNOL, V158, P3270
[10] Chaplin DJ, 1999, ANTICANCER RES, V19, P189

← 1 2 3 4 5 →